IRB Study Number 18-1385

Status Completed

Location Cleveland Clinic Main Campus

Institute Endocrinology and Metabolism Institute



Validation study for the Alertgy non-invasive continuous glucose monitor (ANICGM)

This study aims to validate the glucose readings taken from the ANICGM with an approved outpatient glucose meter in patients with type 2 diabetes.

Inclusion Criteria

Inclusion Criteria

  1. Type 2 diabetes on diet or on pharmacologic treatment for diabetes

  2. Hemoglobin A1c (HbA1c) 7.5-10.0%

  3. Age 18-75 years old

Exclusion Criteria

Exclusion Criteria

  1. Patients taking prandial insulin

  2. Fasting blood glucose by fingerstick <70 mg/dL or >250 mg/dL. Hypoglycemia <70 mg/dL will be treated according to clinic protocol.

  3. Pregnancy

  4. ESRD

  5. Decompensated or acute heart failure

  6. Medications that might cause false readings with glucose meters: acetaminophen, ascorbic acid, dopamine, maltodextrin, mannitol